IAXO-102 (CD14/TLR4 Antagonist) (synthetic)

CHF 295.00
In stock
IAX-600-002-M0011 mgCHF 295.00
More Information
Product Details
Synonyms Methyl 6-deoxy-6-amino-2,3-di-O-tetradecyl-α-D-glucopyranoside
Product Type Chemical


MW 585.94g/mol
CAS 1115270-63-7
Source/Host Chemicals Synthetic.
Purity Chemicals ≥98% (TLC)
Appearance White solid.
Solubility Soluble in Methanol, DMSO and Ethanol 1:1 (vol:vol): >10mM.
Biological Activity

Described to interfere with human, rat and mouse TLR4/CD14 signaling, other species not tested. Optimal working concentration depends upon the type, purity and concentration and of TLR4 ligand, carrier protein such as LPS-binding protein (LBP), soluble and membrane-bound CD14, the presence of TLR4 co-receptors (e.g. CD36) as well as on type and time of read-out (e.g. cytokine measurement in cell culture supernatant) or the biological outcome of in vivo experiments and therefore needs to be determined for each application. Recommended starting concentration: in vitro: 5μM, in vivo (rodent): 3mg/kg.

Identity Determined by NMR and MS.
Declaration Manufactured by Innaxon.
Other Product Data

Reconstitution: For a 2mM stock solution, dissolve total vial content in 853μl (1mg size) or 4,266μl (5mg size) in (1:1) DMSO/Ethanol (vol:vol).

Click here for Original Manufacturer Product Datasheet: Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key InChI=1/C35H71NO5/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-39-33-32(37)31(30-36)41-35(38-3)34(33)40-29-27-25-23-21-19-17-15-13-11-9-7-5-2/h31-35,37H,4-30,36H2,1-3H3
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Use/Stability Stable for at least 1 year after receipt when stored at +4°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • CD14/TLR4 antagonist. Inhibitor of sterile inflammation.
  • Synthetic TLR4/CD14 ligand with TLR4 modulating activities in vitro, and conferring protection against TLR4/CD14-mediated tissue damage and inflammation in vivo. Useful to explore CD14- dependent and TLR4-independent pathways and TLR4 activation by endogenous ligands (e.g. hyaluronic acid oligosaccharides, oxLDL, HMGB1) in sterile inflammation. Shown to inhibit neuropathic pain, secondary necrosis of acute drug-induced liver failure and vascular inflammation, and abdominal aortic aneurysm by blocking non-hematopoietic TLR4 signaling. Useful tool, where inhibition of sterile (auto-) inflammation is desired, without compromising TLR4’s key role in the defense of pathogens.
Product References
  1. Inhibition of lipid a stimulated activation of human dendritic cells and macrophages by amino and hydroxylamino monosaccharides: F. Peri, et al.; Angew. Chem.46, 3308 (2007)
  2. TLR4 receptor as new target to treat neuropathic pain: efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice: I. Bettoni, et al.; Glia 56, 1312 (2008)
  3. Glycolipids and benzylammonium lipids as novel antisepsis agents: synthesis and biological characterization: M. Piazza, et al.; J. Med. Chem. 52, 1209 (2009)
  4. Evidence of a specific interaction between new synthetic antisepsis agents and CD14: M. Piazza, et al.; Biochemistry 48, 12337 (2009)
  5. Exploring the LPS/TLR4 signal pathway with small molecules: F. Peri, et al.; Biochem. Soc. Trans. 38, 1390 (2010) (Review)
  6. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists: F. Peri & M. Piazza; Biotechnol. Adv. 30, 251 (2012) (Review)
  7. Synthetic molecules and functionalized nanoparticles targeting the LPS-TLR4 signaling: A new generation of immunotherapeutics: F. Peri, et al.; Pure Appl. Chem. 84, 97 (2012) (Review)
  8. Toll like receptor 4 antagonist prevents acetaminophen induced acute liver failure in mice: a novel therapeutic strategy: N. Shah, et al.; Gut 61, A28 (2012)
  9. Multivalent glycoconjugates as anti-pathogenic agents. A. Bernardi, et al.; Chem. Soc. Rev. 42, 4709 (2013) (Review)
  10. Toll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update: F. Peri & V. Calabrese; Med. Chem. 57, 3612 (2014) (Review)
  11. A novel small mimetic molecule TLR4 antagonist (IAXO-102) modulates TLR4 proinflammatory signalling and inhibits aortic aneurysms development: C. Huggins, et al.; Atherosclerosis 241, e53 (2015)
  12. Effects of Toll-Like Receptor 4 antagonists against cerebral vasospasm after experimental subarachnoid hemorrhage in mice: F. Kawakita, et al.; Mol. Neurobiol. 54, 6624 (2017)
  13. Selective Toll-Like Receptor 4 antagonists prevent acute blood-brain barrier disruption after subarachnoid hemorrhage in mice: T. Okada, et al.; Mol. Neurobiol. 56, 976 (2019)
  14. Cancer-derived VEGF-C increases chemokine production in lymphatic endothelial cells to promote CXCR2-dependent cancer invasion and MDSC recruitment: J.Y. Chen, et al.; Cancers 11, 1120 (2019)
  15. Increasing the chemical variety of small-molecule-based TLR4 modulators: An Overview: A. Romerio & F. Peri; Front. Immunol. 11, 1210 (2020)
  16. Targeting TLR4-dependent inflammation in post-hemorrhagic brain injury: J.K. Karimy, et al.; Exp. Opin. Ther. Targets 24, 525 (2020) (Review)
  17. Platelets to surrogate lung inflammation in COVID-19 patients: H.K. Bhotla, et al.; Medic. Hypothes. 143, 110098 (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.